MAHE Inaugurates Manipal Hospice and Respite Centre, Revolutionizing Healthcare with Compassion
Manipal (Karnataka) [India], May 6: Manipal Academy of Higher Education (MAHE) marked a significant milestone in Indian healthcare industry with the successful inauguration of Manipal Hospice and Respite Centre (MHRC) at Havanje near Udupi on April 30, 2025. Hon'ble Justice Shri Syed Abdul Nazeer, His Excellency, the Governor of Andhra Pradesh inaugurated nation's one of its kind free of cost palliative care facility.
Dedicating the high impact social initiative of MAHE, hon'ble Governor Justice Shri Syed Abdul Nazeer said, "MAHE's initiative to establish MHRC reflects a noble commitment to alleviate the suffering of those with advanced and terminal illnesses--treating compassionate care as a fundamental human right."
Expressing deep concern over the alarming rise in cancer cases, the Governor highlighted the healthcare system's gaps. "India reported 1.4 million new cancer cases in 2022, and yet less than 10% of patients in need receive palliative care. MHRC is a path-breaking step that shifts away from hospital-centric models and instead provides affordable, humane care--greatly reducing emotional and financial distress on families," hon'ble Governor noted.
Applauding MHRC's values, the Governor added, "This centre upholds the spirit of 'Manava Seve Madhava Seve'--service to mankind is service to God. By offering free, personalized, and dignified end-of-life care through philanthropic support, MHRC sets a benchmark in healthcare delivery. It is a visionary model that deserves to be replicated nationwide."
Vasanti R Pai, Trustee, MAHE Trust, Dr Ranjan Pai, President MAHE Trust, Registrar of Academy of General Education (AGE), and Chairman of Manipal Education and Medical Group (MEMG), Ashoka Pai, President of Dr TMA Pai Foundation, Dr HS Ballal, Pro-Chancellor of MAHE, Lt Gen (Dr) MD Venkatesh, Vice Chancellor, MAHE, Shri Kota Srinivas Poojary, Member of Parliament, Shri Yashpal Anand Suvarna, Member of Legislative Assembly, and Abhaya Chandra Jain, former Member of Legislative Assembly participated in this high profile event.
Senior officials of MAHE, Dr Narayana Sabhahit, Pro Vice Chancellor (Technology & Science), Dr Sharath K Rao, Pro Vice-Chancellor (Health Sciences), Dr Madhu Veeraraghavan, Pro Vice Chancellor (Management, Law, Humanities, and Social Sciences), Dr Dilip G Naik, Pro Vice Chancellor-Mangalore, Dr Raviraja NS, Chief Operating Officer - Operations, Dr P Giridhar Kini, Registrar and Dr. Vinod V. Thomas, Registrar (Evaluation),Dr Anand Venugopal, Chief Operating Officer-Teaching Hospitals, MAHE, Manipal, Dr. Avinash Shetty, Medical Superintendent, Kasturba Hospital Manipal (KMC Manipal), Dr Padmaraj Hegde, Dean, Kasturba Medical College Manipal, Dr Naveen Salins, Associate Dean and Professor & Head of the Department of Palliative Medicine and Supportive Care at KMC Manipal and Dr Seema Rao, Director, MHRC were present on the occasion.
A First in India: Free Palliative Care on a Lush Green Campus
The MHRC, located just outside Manipal on a lush 12-acre campus by the Swarna River, with 78% green zone prioritizing calm, and open environment that promotes well-being, is designed to offer compassionate care for patients facing serious and life-limiting illnesses. The facility will begin operations in June 2025 and will provide a full range of palliative and respite care services, completely free of charge. This 100-beded facility is the only hospice in India attached to both a medical college and tertiary care hospital, that caters to both cancer and non-cancer conditions. MHRC will provide innovative care models while training the next generation of palliative care specialists. The patient-centered approach will be further enhanced through innovative telehealth programs, ensuring accessible care for all who need it regardless of location.
MHRC combines both hospice (end-of-life) and respite (short-term relief) services under one roof, offering comprehensive pain and symptom management, wound and stoma care, nursing and rehabilitation services. A multidisciplinary team including doctors, nurses, counsellors, psychologists, physiotherapists, occupational therapists, social workers, and volunteers will provide holistic care that addresses physical, emotional, spiritual, and social needs. MHRC emphasizes dignity therapy, legacy work, rehabilitation, and family empowerment, along with medical care. It also integrates education and bereavement support, ensuring patients and their families are prepared and supported through every stage of serious illness and loss.
The Manipal Academy of Higher Education (MAHE) is an Institution of Eminence Deemed-to-be University. MAHE offers over 400 specializations across the Health Sciences (HS), Management, Law, Humanities & Social Sciences (MLHS), and Technology & Science (T & S) streams through its constituent units at campuses in Manipal, Mangalore, Bengaluru, Jamshedpur, and Dubai. With a remarkable track record in academics, state-of-the-art infrastructure, and significant contributions to research, MAHE has earned recognition and acclaim both nationally and internationally. In October 2020, the Ministry of Education, Government of India, awarded MAHE the prestigious Institution of Eminence status. Currently ranked 4th in the National Institutional Ranking Framework (NIRF), MAHE is the preferred choice for students seeking a transformative learning experience and an enriching campus life, as well as for national & multi-national corporates looking for top talent.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
an hour ago
- India Today
Trump's war on Indian drugs risks a global supply shock
India, a top-five supplier of medicines to the US, is now in the crosshairs of Donald Trump's latest trade offensive. In a move that could ripple through hospitals and households across America, the US president is planning tariffs as high as 250 per cent on imported drugs. In this sector, India plays a crucial US president has already proposed 200 per cent tariffs on pharmaceutical imports and reportedly conveyed this to Ireland's prime minister. Ireland is the largest exporter of drugs to America. India's USD 12.5 billion shipments of low-cost generics make it a critical link in the US healthcare chain — and a vulnerable Why it matters: The US relies on India for affordable generics. Steep tariffs could spike drug prices, strain supply chains, and hit both Indian exporters and American patients. Markets are already flashing numbers:$12 billion: Value of Indian drug exports to the US in 2024$10.5 billion: US trade deficit in pharma as of May 202525–250%: Range of proposed tariffs on Indian medicines+9 percentage points: Rise in average US pharma tariffs if 25% levy holds$50 billion: Total size of India's pharma market$26.5 billion: Value of India's total drug exports5th: India's ranks among US pharma suppliers after Ireland, Germany, Italy, and the NetherlandsIn-depth: India is a pharmaceutical powerhouse. It manufactures one in every five generic drugs used in the US, earning its nickname, 'pharmacy of the world'. These low-cost treatments keep healthcare affordable for millions of Trump's new tariffs risk unravelling that system. Industry experts say even a 25 per cent tariff could lift average pharma duties by nine points, a shock for hospitals, insurers, and patients. The threat of further hikes has already rattled April, the S&P 1500 Pharma Index has fallen more than India's Nifty Pharma. Investors expect pain, not protection, for US while the goal is to shift manufacturing home, pharma executives say the tariffs will only raise costs and delay investments. Many drug ingredients still come from abroad. The result could be supply gaps, higher prices, and worse picture: When Trump took office, the average US tariff rate was just 2.5 per cent. It has since surged to between 17 and 19 per cent, depending on the estimate. The Atlantic Council warns it could reach 20 per cent, the highest in a century, as another round of duties kicks in on before Thursday midnight, Trump claimed that billions of dollars would start pouring into the US thanks to the tariffs targeting nearly 70 US trade partners with duties from 10 to 41 per cent. Trump launched a tariff campaign in April, accusing other countries of unfair imposed a 25 per cent tariff on Indian imports, adding to the 25 per cent levy announced last week. This higher duty takes effect in 21 days, as stated in the order, leaving room for negotiations. However, pharmaceutical products are on the exemption list at the used to protect factory jobs. Today, they're tools of foreign policy. Trump's evolving doctrine is part punishment, part politics — and the drug industry could be the latest they said: 'In one year, one and a half years maximum, it's going to go to 150 per cent, and then it's going to go to 250 per cent because we want pharmaceuticals made in our country,' Donald Trump told CNBC in an interview.- EndsTune InMust Watch
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Weighty issues: India's rush to make weight-loss drugs demands user caution
The global market for weight-loss drugs is estimated at $100 billion by the end of the decade premium Business Standard Editorial Comment Mumbai Listen to This Article Indian pharmaceutical companies are preparing for weighty gains when the patent for semaglutide, the active pharmaceutical ingredient (API) used in drugs for weight loss and the treatment of diabetes, lapses in 2026 in 100 countries, including India, Canada, and Brazil. Sold by Novo Nordisk under the brand names Ozempic and Wegovy, the drugs have proven to be blockbusters for the Danish pharma major, generating $25 billion in revenues in 2024 alone. No surprise, then, that Indian drugmakers have spotted a huge opportunity and are preparing to launch significantly cheaper generic versions of semaglutide. All the major names of the domestic
The Hindu
2 hours ago
- The Hindu
Pakistani Hindu doctor, stateless for four years, gets Indian citizenship
A doctor from Pakistan, 'stateless' for the past four years, has been registered as an Indian citizen, the Gujarat High Court was informed on Thursday (August 7, 2025). Nanikraz Khanoomal Mukhi (53), who had a sonography clinic in Pakistan's Hyderabad, chose to move to India in 2009 for his children's education and to escape possible religious persecution. Dr. Mukhi was registered as an Indian on August 5 under Section 5 (1) (A) of the Citizenship Act, 1955 by the office of District Magistrate, Ahmedabad. The Section prescribes citizenship to a person of Indian origin who is ordinarily resident in India for seven years before making an application for registration and is not an illegal migrant. The Hindu reported about Dr. Mukhi's case on July 19. Dr. Mukhi had been running from pillar to post to get registered as an Indian since 2021, when he renounced his Pakistani passport after receiving a letter from the Ahmedabad Collector's office that the application has been processed and he would receive the citizenship soon. He applied for citizenship in 2016. Clinic sealed As his application remained stuck in red tape, his clinic in Ahmedabad was sealed by the health officials as he was not an Indian citizen. Dr. Mukhi moved the Gujarat High Court against the Union of India and the State of Gujarat on April 30. After the Union government's counsel informed the court on Thursday that Dr. Mukhi has been granted citizenship, he decided to withdraw the petition. 'As an Indian I will get legal rights and the right to practice as a medical doctor now. I can apply for a voter card and a passport. I did not have any rights for the past four years. I had no nationality so far. It is a huge relief,' Dr. Mukhi told The Hindu. He added that he would apply for a medical licence with the Gujarat Medical Council soon. Dr. Mukhi's wife, who had applied for citizenship with him, has been granted the naturalisation certificate. His three children acquired citizenship after they registered under the Citizenship Amendment Act (CAA), 2019, which became effective on March 11, 2024. Citizenship is a subject under the Union List and is decided by the Ministry of Home Affairs. The MHA has delegated powers to district magistrates/collectors of 31 districts in nine States, including Gujarat, to grant citizenship to legal migrants (who entered on passport/visa) from the Hindu, Sikh, Buddhist, Jain, Parsi and Christian communities from Pakistan, Bangladesh and Afghanistan under Section 5 (by registration) and Section 6 (naturalisation) of the Citizenship Act, 1955.
